Altre lingue Eterna Therapeutics Inc.

Azioni

ERNA

US1140822099

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
2,15 ^USD	0,00%		0,00%	+19,78%

14/03	Eterna Therapeutics Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
20/02	Eterna Therapeutics Inc. annuncia la nomina di Peter Cicala, JD, nel suo Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

North American Morning Briefing : Inflation -2-	15/03
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	20/02
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors	20/02
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee	16/02
Eterna Therapeutics Inc. Announces Management Changes	19/01
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	03/01
Eterna Therapeutics Inc Announces Chief Executive Officer Changes, Effective January 1, 2024	21/12
Eterna Therapeutics Inc Appoints Sanjeev Luther as President and Member of the Board of Directors, Effective January 1, 2024	21/12
Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board	20/12
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	20/12
Eterna Therapeutics Selling $9.2 Million of Convertible Promissory Notes, Accompanying Warrants	15/12
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	15/12
Eterna Therapeutics Inc. announced that it expects to receive $9.2 million in funding	14/12
Eterna Therapeutics Inc. announced that it has received $1.5 million in funding	08/12
Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited	16/11
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Eterna Therapeutics Inc. Appoints James Bristol to Its Board of Directors	01/11
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors	01/11
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	30/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eterna Therapeutics Inc.

Azioni

ERNA

US1140822099

Altre lingue

Filtri